Application of Standardized Green Channel Treatment System for Ischemic Stroke in Xi 'an

NCT ID: NCT05424978

Last Updated: 2024-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

3600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-06-01

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective: To observe the practical application of the standardized green channel treatment system for stroke in Xi 'an in the real world. Methods: Clinical data and information of patients with acute ischemic stroke who received standardized green channel treatment for stroke were collected, and a multicenter observational clinical study was carried out in the real world to evaluate the prognosis, mortality, incidence of asymptomatic and symptomatic cerebral hemorrhage, incidence of pneumonia, and recurrence rate of stroke after 90 days.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The standardized green channel treatment system for acute ischemic stroke includes: Triage nurse triage timely, rapid assessment emergency doctor, suspected stroke the green channel, immediately start in the green channel of stroke accompanied by doctors and nurses stroke patients improve CT examination, intravenous thrombolysis or CT room, emergency room if considering large vascular lesions and the onset time in 6 hours, and rapidly to international for endovascular treatment, if the onset time of more than 6 hours, Rapid evaluation of ischemic penumbra and vascular occlusion by multi-mode imaging. If there are indications for endovascular treatment, go to the cath room for endovascular treatment as soon as possible.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ischemic Stroke Thrombolysis Endovascular Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Standardized green channel treatment methods for stroke

The measures include six measures: timely triage by triage desk nurses; Rapid evaluation by emergency room physician; If stroke is suspected, the green channel for nosocomial stroke should be activated immediately. Stroke greenway doctors and stroke nurses accompanied patients to complete CT examination; Intravenous thrombolysis in emergency rooms or CT rooms; Suspected macrovascular disease, if the onset time is less than 6 hours, quickly go to the catheter room for intravascular treatment; If the onset time was more than 6 hours, multi-mode imaging was used to quickly evaluate the ischemic penumbra and vascular occlusion, and then the patients were sent to the catheter room for intravascular treatment as soon as possible.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years old;
* Consistent with the diagnosis of acute ischemic stroke;
* 24 hours from onset to enrollment;
* Informed consent

Exclusion Criteria

* Patients who refuse to receive intravenous thrombolysis or intravascular intervention (including intravascular mechanical thrombolysis and arterial thrombolysis);
* Stroke patients caused by brain tumor, brain trauma and blood diseases;
* Those with a history of stroke and sequelae affecting the outcome assessment, namely, mRS 2 points before the onset of this stroke;
* Combined with claudication osteoarthritis rheumatoid arthritis gout arthritis and other limb dysfunction and affect the neurological function examination;
* Patients with severe hepatic and renal insufficiency (Note: Hepatic insufficiency refers to ALT or AST values greater than 2 times the upper normal limit; Renal insufficiency refers to blood creatinine value greater than 2 times the normal upper limit);
* Suffering from other serious life-threatening diseases with an expected survival time of less than 3 months;
* Other diseases that limit neurological function evaluation or affect patient follow-up;
* A woman planning to be pregnant or breastfeeding;
* Currently participating in other clinical trials;
* Refuse to participate in the registration of investigators
Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Xi'an No.3 Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ye Tian, Doctor

Role: STUDY_DIRECTOR

The dean

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Xi 'an No.3 Hospital

Xi'an, Shaanxi, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mingze Chang, Doctor

Role: CONTACT

8615609250698

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mingze Chang, Doctor

Role: primary

8615609250698

Shilin Li, Doctor

Role: backup

8615398076154

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SYLL-2021-024

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.